EN
EN
FR
ES
PT
AR
RU
DE
IT
NL
TH
KO
VI
ID
Home
Kexing Biopharm
About Us
Kexing Brand
Brand Connotation
Corporate Culture
Honors
History
Global Business
Global Commercial Cooperation Strategy
Commercialization platform
Commercialization capability
Commercial Cooperation Graph
R&D and Innovation
Global R&D Center
R&D field
Animal Vaccine
Synthetic Biology
SANCTINUS
Our Medicines
Infliximab for Injection
Bevacizumab Injection
Adalimumab Solution for Injection
Paclitaxel for Injection(Albumin-Bound)
Human Erythropoietin Injection
Human Granulocyte Colony-stimulating Factor Injection
Combined Clostridium and Bifidobacterium,Live
Human Interferon α1b for Injection
Kehuang Capsule
Entecavir Tablets
α-ketoglutarate(AKG)
5-aminnolevulinic acid (5-ALA)
Recombinant Collagen Repair Mask
Recombinant Collagen Anti-Wrinkle Single Use Essence
Quality Control
Quality system
Compliant production
Pharmacovigilance
ESG
Global health
Support Community
Environmental protection
News
News and information
Video Center
Contact
Contact Us
Join Us
NEWS AND INFORMATION
Home
/
News
/
News and information
/
Kexing Biopharm...
Kexing Biopharm's Product Catalog (Core Product)
Article source：Kexing Biopharm
Jun 17,2025
View： 1796
LABEL:
< Kexing Biopharm's Product Introduction
Kexing Biopharm: A leader in China Recombinant Protein Therapeutics Industry >
BACK TO LIST
Related News
Oct 09,2023
Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery
READ MORE >>
Feb 04,2024
Human Erythropoietin Injection: Benefits, Risks & Guidelines
READ MORE >>
Jul 13,2023
Kexing Biopharm won the sole agency for the first-time generic drug of infliximab, demonstrating strong superiority in ...
READ MORE >>
Apr 09,2024
R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm
READ MORE >>
Nov 03,2023
Unlocking Health: Exploring the Power of Erythropoietin 36000IU
READ MORE >>
Feb 21,2024
What are the frequently asked questions about recombinant protein?
READ MORE >>
Home
Kexing Biopharm
About Us
Kexing Brand
Brand Connotation
Corporate Culture
Honors
History
Global Business
Global Commercial Cooperation Strategy
Commercialization platform
Commercialization capability
Commercial Cooperation Graph
R&D and Innovation
Global R&D Center
R&D field
Animal Vaccine
Synthetic Biology
SANCTINUS
Our Medicines
Infliximab for Injection
Bevacizumab Injection
Adalimumab Solution for Injection
Paclitaxel for Injection(Albumin-Bound)
Human Erythropoietin Injection
Human Granulocyte Colony-stimulating Factor Injection
Combined Clostridium and Bifidobacterium,Live
Human Interferon α1b for Injection
Kehuang Capsule
Entecavir Tablets
α-ketoglutarate(AKG)
5-aminnolevulinic acid (5-ALA)
Recombinant Collagen Repair Mask
Recombinant Collagen Anti-Wrinkle Single Use Essence
Quality Control
Quality system
Compliant production
Pharmacovigilance
ESG
Global health
Support Community
Environmental protection
News
News and information
Video Center
Contact
Contact Us
Join Us
Article source：Kexing Biopharm
Jun 17,2025
View：
1796 
BACK TO LIST
Oct 09,2023
